Research Peptide Cagrilintide 10mg for Weight Loss and Satiety

Overview

Cagrilintide is a long-acting amylin analogue. Research has been published regarding its roles in metabolic regulation, satiety signaling, and the control of gastric emptying in both animal and clinical study models. Engineered to prolong receptor activity, the medcication reportedly has a half-life of approximately one week, enabling the use of a once-weekly dosing regimen in published trials. This product consists of 10 mg of lyophilized Cagrilintide powder, which requires reconstitution with a sterile diluent for laboratory use.

What is Cagrilintide?

Amylin is a peptide hormone co-secreted with insulin by pancreatic beta cells; it plays a role in regulating satiety and postprandial glucose metabolism. Cagrilintide is a synthetic, acylated amylin analogue designed to resist rapid clearance and thereby extend medciation activity; in contrast to the first-generation analogue pramlintide—which has a half-life of only about 50 minutes—Cagrilintide exhibits an extended half-life of approximately 180 hours. Published literature describes it as an agonist of both the amylin receptor and the calcitonin receptor.

How Cagrilintide Works in the Body

Cagrilintide is a long‑acting amylin analogue. It activates amylin receptors to boost satiety, slow gastric emptying and curb appetite, helping support body weight management by regulating energy balance.

Mechanism of Action

Published research indicates that amylin analogues such as cagrilintide delay gastric emptying and modulate glucagon signaling by acting on satiety-regulating neural circuits in the area postrema and the hypothalamus. The dual agonist activity of cagrilintide at amylin and calcitonin receptors is a current area of ​​intense research interest; researchers have investigated how these pathways interact with incretin signaling in both preclinical and clinical models. Research into the precise molecular mechanisms and downstream effects is ongoing.

Published Research

Published studies on cagrilintide encompass preclinical models as well as human clinical trials with metabolic endpoints. Areas of research include:
· Amylin and calcitonin receptor signaling
· Studies on satiety and food intake in animal and clinical models
· Gastric emptying and postprandial glucose regulation
· Combination therapy with GLP-1 receptor agonists
· Pharmacokinetic profile of once-weekly administration
· Cagrilintide has not yet received TGA approval for any therapeutic indication.